How to buy Cogstate (CGS) shares
Learn how to easily invest in Cogstate shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Cogstate is a health information services business based in Australia. Cogstate shares (CGS) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Cogstate has a trailing 12-month revenue of around $32.7 million. If you're looking to buy shares, check out the steps below.
How to buy shares in Cogstate
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Cogstate. Find the share by name or ticker symbol: CGS. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cogstate reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of Cogstate. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
Cogstate stock price (ASX:CGS)Use our graph to track the performance of CGS stocks over time.
Cogstate shares at a glance
|52-week range||$0.8 - $2.68|
|50-day moving average||$2.3564|
|200-day moving average||$1.7428|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.041|
Compare share trading platforms
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Cogstate stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Cogstate price performance over time
|1 week (2022-01-13)||-8.30%|
|1 month (2021-12-21)||0.87%|
|3 months (2021-10-21)||3.57%|
|6 months (2021-07-21)||61.67%|
|1 year (2021-01-21)||109.95%|
|2 years (2020-01-20)||388.42%|
|3 years (2019-01-17)||283.79%|
|5 years (2017-01-20)||74.73%|
Is Cogstate under- or over-valued?
Valuing Cogstate stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cogstate's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cogstate's P/E ratio
Cogstate's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 60x. In other words, Cogstate shares trade at around 60x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Cogstate's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.5 million (£0.0 million).
The EBITDA is a measure of a Cogstate's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$32.7 million|
|Operating margin TTM||11.73%|
|Gross profit TTM||$17.5 million|
|Return on assets TTM||5.75%|
|Return on equity TTM||28.08%|
|Market capitalisation||$424.7 million|
TTM: trailing 12 months
Cogstate share dividends
We're not expecting Cogstate to pay a dividend over the next 12 months.
Have Cogstate's shares ever split?
Cogstate's shares were split on 5 August 2008.
Cogstate share price volatility
Over the last 12 months, Cogstate's shares have ranged in value from as little as $0.8 up to $2.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Cogstate's is -0.2537. This would suggest that Cogstate's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Cogstate has bucked the trend.
Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain health applications in Australia and internationally. The company's services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. It operates in Clinical Trials and Healthcare segments. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Healthcare segment provides Cognigram, a system for regular and standardized testing to assist in the early detection of cognitive decline. As of June 30, 2021, it had participated in approximately 1,800 academic research studies in approximately 200 indications. Cogstate Limited was incorporated in 1999 and is based in Fitzroy, Australia.
Stocks similar to Cogstate
Cogstate in the news
Cogstate : Investor Update
Cogstate : Business Update and December 2021 Quarter Cashflow
Frequently asked questions
More guides on Finder
N95 vs KN95 face masks: What’s the difference?
It can be confusing knowing the difference between a KN95 and N95 face mask. We look at them both and where to buy them online.
9 tips for founders I learned from launching a startup in a pandemic
Here’s what Ryan Edwards-Pritchard learned so far about building a startup in the grips of a pandemic.
How to watch Arsenal vs Liverpool in the Carabao Cup live and free in Australia
Arsenal and Liverpool are locked at 0-0 ahead of their Carabao Cup semi-final second leg this week.
Australian rapid antigen test statistics
Heres how stock levels and prices are holding up for RATs in Australia.
How to Stake Olympus DAO (OHM)
Learn how to stake OHM and receive high yield from one of DeFi's most ambitious experiments.
Retroactive airdrop farming: How to prepare yourself for 2022
Being early to a new DeFi ecosystem can be very profitable – here's how to game the system and potentially earn yourself some tokens.
What is reporting season and why does it matter to investors?
Reporting season is a 2-week or so period where investors can see the results for a large number of publicly traded companies.
Bank First Green Personal Loan review
Bank First’s variable rate green personal loan can be used to make environmentally friendly purchases for your home.
Today’s ASX top stocks: Blackstone Minerals (BSX ↑12.7%), Weebit Nano (WBT ↑9.7%)
The 10 biggest movers on the ASX for Thursday 20 January 2022.
Ask an Expert